Difference between revisions of "V-HeFT Trial"
From Gomerpedia
| Line 2: | Line 2: | ||
The '''V-HeFT Trial''', which stands for '''very hefty''', was a clinical trial published in the ''[[New England Journal of Medicine]]'' establishing that therapy with isosorbide dinitrate and hydralazine reduced mortality in patients systolic heart failure. Hefty findings indeed. Especially in an era before [[ACE Inhibitor|ACEI inhibitors]], ACE bandages, and beta blockers like [[Metoprolol|metoprolol]]. | The '''V-HeFT Trial''', which stands for '''very hefty''', was a clinical trial published in the ''[[New England Journal of Medicine]]'' establishing that therapy with isosorbide dinitrate and hydralazine reduced mortality in patients systolic heart failure. Hefty findings indeed. Especially in an era before [[ACE Inhibitor|ACEI inhibitors]], ACE bandages, and beta blockers like [[Metoprolol|metoprolol]]. | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
[[Category:Cardiology]] | [[Category:Cardiology]] | ||
| − | |||
Revision as of 07:42, 12 July 2017
The V-HeFT Trial, which stands for very hefty, was a clinical trial published in the New England Journal of Medicine establishing that therapy with isosorbide dinitrate and hydralazine reduced mortality in patients systolic heart failure. Hefty findings indeed. Especially in an era before ACEI inhibitors, ACE bandages, and beta blockers like metoprolol.
|
Fun Stuff
|
